129 related articles for article (PubMed ID: 9788132)
1. MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers.
Martí-Bonmatí L; Lonjedo E; Poyatos C; Casillas C
Invest Radiol; 1998 Oct; 33(10):717-22. PubMed ID: 9788132
[TBL] [Abstract][Full Text] [Related]
2. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Federle MP; Peterson MS; Oliver JH; Davis PL; Confer SR
Radiology; 1996 Feb; 198(2):567-72. PubMed ID: 8596867
[TBL] [Abstract][Full Text] [Related]
3. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.
Martí-Bonmatí L; Fog AF; de Beeck BO; Kane P; Fagertun H
Eur Radiol; 2003 Jul; 13(7):1685-92. PubMed ID: 12835986
[TBL] [Abstract][Full Text] [Related]
6. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
7. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
8. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
9. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies.
Rummeny EJ; Torres CG; Kurdziel JC; Nilsen G; Op de Beeck B; Lundby B
Acta Radiol; 1997 Jul; 38(4 Pt 2):638-42. PubMed ID: 9245957
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of healthy from cirrhotic livers. Evaluation of parametric images after contrast administration in magnetic resonance imaging.
Martí-Bonmatí L; Masiá L; Casillas C; Ronchera-Oms CL; Torrijo C
Invest Radiol; 1996 Dec; 31(12):768-73. PubMed ID: 8970879
[TBL] [Abstract][Full Text] [Related]
11. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
[TBL] [Abstract][Full Text] [Related]
12. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
[TBL] [Abstract][Full Text] [Related]
13. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
14. Using contrast-enhanced MR cholangiography with IV mangafodipir trisodium (Teslascan) to evaluate bile duct leaks after cholecystectomy: a prospective study of 11 patients.
Vitellas KM; El-Dieb A; Vaswani KK; Bennett WF; Fromkes J; Ellison C; Bova JG
AJR Am J Roentgenol; 2002 Aug; 179(2):409-16. PubMed ID: 12130442
[TBL] [Abstract][Full Text] [Related]
15. Sequence optimization in mangafodipir trisodium-enhanced liver and pancreas MRI.
Wang C; Johansson L; Western A; Fagertun H; Ahlström H
J Magn Reson Imaging; 1999 Feb; 9(2):280-4. PubMed ID: 10077025
[TBL] [Abstract][Full Text] [Related]
16. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.
Bartolozzi C; Donati F; Cioni D; Procacci C; Morana G; Chiesa A; Grazioli L; Cittadini G; Cittadini G; Giovagnoni A; Gandini G; Maass J; Lencioni R
Eur Radiol; 2004 Jan; 14(1):14-20. PubMed ID: 14730384
[TBL] [Abstract][Full Text] [Related]
17. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.
Vogl TJ; Hamm B; Schnell B; McMahon C; Branding G; Lissner J; Wolf KJ
J Magn Reson Imaging; 1993; 3(1):51-8. PubMed ID: 8381314
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results.
Sahani DV; O'Malley ME; Bhat S; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(2):216-22. PubMed ID: 11884777
[TBL] [Abstract][Full Text] [Related]
19. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool.
Helmberger TK; Laubenberger J; Rummeny E; Jung G; Sievers K; Döhring W; Meurer K; Reiser MF
Eur Radiol; 2002 Jan; 12(1):62-70. PubMed ID: 11868075
[TBL] [Abstract][Full Text] [Related]
20. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics.
Kim JH; Kim MJ; Park YN; Lee JT; Kim BR; Chung JB; Choi JS; Kim KS; Kim KW
Clin Radiol; 2008 Nov; 63(11):1195-204. PubMed ID: 18929037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
